Volinanserin

Drug Profile

Volinanserin

Alternative Names: 100,907; M 100907; MDL 100907

Latest Information Update: 13 Mar 2009

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Insomnia; Schizophrenia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 May 2008 Efficacy data from the phase III NOCTURNE trial in insomnia released by sanofi-aventis
  • 13 Feb 2007 Volinanserin is still in phase II trials for Insomnia in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top